Rbp4 quantikine elisa kit

Non-target shRNA control (SHC002) and RBP4shRNAs (TRCN0000060038 [#1] and TRCN0000060039 [#2]) were purchased from Sigma. STRA6shRNAs (TRCN0000128799 [#2] and TRCN0000129158 [#1]) and EGFP (RHS4459) were from Open Biosystems. Epidermal growth factor (EGF) was from Stem Cell Technologies and basic fibroblast growth factor (FGF) was from Peprotech. Etoposide, insulin, and heparin were purchased from Sigma. Viable cells were counted after trypan blue staining using Countess II FL (Life Technologies). Human RBP4 in serum samples of patients was quantified using an RBP4 Quantikine ELISA kit (R&D Systems) following the manufacturer's protocols.

Total triglyceride (TG) concentrations of the serum and liver were measured by a micro-plate reader (Bio-Tek, USA) using corresponding enzymatic assays (#90-63701, Wako). Especially, the concentrations of hepatic TG, extracted with chloroform/methanol (2:1, v/v) as reported in our previous study 29 (link), were also determined using the above commercial enzymatic assay. The total lipid content in the liver was determined gravimetrically after extraction. Moreover, the serum RBP4 concentrations were respectively carried out on humans (#DRB400) and mice (#DRBP40) using corresponding RBP4 Quantikine ELISA kit (R&D Systems, USA). Furthermore, the serum levels of insulin were measured by ELISA kit (Millipore, USA). Total glycogen in the liver was measured according to the methods of Glycogen Assay Kit (BioVision, USA). In addition, the concentrations of serum GH and IGF-1 were also carried out on humans using corresponding enzymatic assays, respectively (Huijia Biotechnology, China).